# Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

> clinical trial · VERIFIED · 2026-07-09

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Metastatic Colorectal Cancer

- Company: National Cancer Institute (NCI)
- Sector: Metastatic Colorectal Cancer
- Primary source: https://clinicaltrials.gov/study/NCT06149481

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.